邁為股份(300751.SZ):與隆基系簽署5.439億元的日常經營合同
格隆匯12月19日丨邁為股份(300751.SZ)公佈,公司子公司蘇州邁為自動化設備有限公司(“邁為自動化”)在近期與隆基綠能科技股份有限公司之全資孫公司西安隆基樂葉光伏科技有限公司、陝西隆基樂葉光伏科技有限公司(“隆基系”)簽署了多份日常經營合同,合同累計金額5.439億元,佔公司2018年度經審計主營業務收入的69.03%。
邁為自動化與上述交易對手簽訂的銷售合同,金額合計5.439億元,佔公司2018年度經審計營業收入的69.03%,預計對公司本年及以後年度經營業績產生積極影響(最終以公司經會計師審計的定期報告為準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.